证券代码：300143 证券简称：盈康生命 公告编号：2025-020 盈康生命科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过决议的情况。 一、会议召开和出席的情况 （一）会议召开情况 1、盈康生命科技股份有限公司（以下简称"公司"）2024 年年度股东大会通知 已于 2025 年 3 月 29 日以公告的形式向全体股东发出，具体内容详见公司刊登于巨 潮资讯网（www.cninfo.com.cn）的相关公告。 2、召开时间：现场会议召开时间为 2025 年 4 月 18 日（星期五）下午 14:30。 （1）通过深圳证券交易所交易系统投票 2025 年 4 月 18 日 9:15-9:25，9:30-11:30 和 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票 2025 年 4 月 18 日 9:15-15:00。 3、会议召开地点：山东省青岛市崂山区海尔路一号盈康一生大厦董事会议室。 4 ...

Group 1 - The core point of the article is that Yingkang Life plans to acquire a 51% stake in Changsha Kexin Oncology Hospital for 357 million yuan, which will allow it to gain control and consolidate the hospital's financials [2] - Changsha Kexin, established in 2015, is a tertiary oncology specialty hospital with 420 beds and reported revenue of 273 million yuan and net profit of 33.43 million yuan for the first three quarters of 2024 [2] - The hospital has committed to achieving net profits of no less than 57 million yuan, 58 million yuan, and 60 million yuan for the years 2025 to 2027, totaling 175 million yuan, which represents a significant increase of 73%-82% compared to historical performance [2] Group 2 - The acquisition is part of Yingkang Life's "1+n" strategy, which aims to establish a regional center hospital that supports multiple satellite hospitals [2] - Currently, Yingkang Life operates three owned hospitals and seven managed institutions, with projected medical service revenue of 1.192 billion yuan in 2024, where oncology revenue is expected to account for 31.9% [3] - Following the acquisition, Yingkang Life's total assets are reported at 3.537 billion yuan, with a debt ratio of 29.93%, indicating that total liabilities may increase post-acquisition [3]

Core Viewpoint - Yingkang Life announced the acquisition of 51% equity in Changsha Kexin Oncology Hospital for 357 million yuan, with an overall valuation of approximately 700 million yuan, resulting in a premium rate of 1429.99%, significantly exceeding the average merger premium in the healthcare industry [1][2] Group 1: Acquisition Details - The acquisition price of 357 million yuan corresponds to Changsha Kexin's net assets of 46.14 million yuan as of September 2024, indicating a high premium rate [1] - The acquisition will create approximately 280 million yuan in goodwill, accounting for 78% of the purchase price [2] Group 2: Financial Performance and Risks - Changsha Kexin has committed to net profits of 57 million, 58 million, and 60 million yuan for the years 2025 to 2027, respectively, but has only achieved a net profit of 33.42 million yuan in the first three quarters of 2024, indicating challenges in meeting these targets [2] - The realization of these profit commitments is dependent on uncontrollable factors such as local medical insurance policies and competition from public hospitals, which adds uncertainty to the performance outlook [2] Group 3: Historical Context and Concerns - Yingkang Life has previously faced issues with high premium acquisitions, such as the 2015 acquisition of Maxip, which resulted in 947 million yuan in goodwill and 804 million yuan in impairments by 2021 [3] - High premium acquisitions lead to increased goodwill on the balance sheet, which is essentially a prepayment for the future profitability of the acquired entity; if performance does not meet expectations, goodwill impairment will directly impact the company's profits [3] Group 4: Strategic and Operational Challenges - The strategic synergy of the acquisition is questionable, as Yingkang Life's core competencies lie in medical device R&D and oncology treatment technology, while Changsha Kexin operates as a regional hospital reliant on localized medical services [4] - The acquisition may dilute core business resources, as the high cash outflow could affect the development of key projects like high-end imaging equipment and AI diagnostic algorithms, leading to a diversion of management focus [4] - The regional oncology market is highly competitive, with public hospitals attracting patients away from private facilities, making it difficult for Changsha Kexin to maintain its market position [5]

Financial Performance - In 2024, Yingkang Life achieved revenue of CNY 1.559 billion, a year-on-year increase of 6.01% [9] - The medical services segment generated revenue of CNY 1.192 billion, up 3.76% year-on-year, while the medical device segment saw revenue of CNY 367 million, a growth of 14.05% [9] - The net profit attributable to shareholders reached CNY 115 million, reflecting a year-on-year growth of 14.92% [9] Cost Management - The company optimized its cost structure, with management expenses decreasing by 0.1 percentage points, sales expenses down by 0.6 percentage points, and financial expenses reduced by 0.1 percentage points [2][3] - R&D expenses amounted to CNY 54.52 million, accounting for 14.86% of medical device revenue, with a commitment to maintain reasonable levels of R&D investment [3] Strategic Initiatives - Yingkang Life is actively embracing AI technology to enhance operational efficiency and service quality, with a focus on a "three-full" concept: full participation, full coverage, and full process [7] - The company is transitioning from a traditional medical group to a health management technology company, leveraging AI to improve service efficiency and patient experience [8] Acquisition of Changsha Kexin Hospital - The acquisition of Changsha Kexin Hospital, a tertiary cancer specialty hospital, is expected to enhance Yingkang Life's business scale and profitability [11] - The hospital reported an audited revenue of CNY 273 million and a net profit of CNY 33.43 million for the first nine months of 2024, with performance commitments for the next three years [6] Market Outlook - The aging population in China is driving the growth of the silver economy, with increasing demand for healthcare services [14] - The private cancer hospital market is projected to reach CNY 106.7 billion by 2025, with the overall cancer medical service market expected to grow to CNY 700.3 billion [14] - The medical device industry is anticipated to surpass CNY 1.2 trillion in market size in 2024, supported by government initiatives and technological advancements [14]

星标 ★ IPO日报 精彩文章第一时间推送 背靠海尔集团公司（下称"海尔集团"），上市公司盈康生命科技股份有限公司（下称"盈康生命"，300143.SZ）即将迎来第四家自有医院。 近期，盈康生命发布公告，拟以3.57亿元现金收购长沙珂信肿瘤医院有限公司（下称"长沙珂信"）51%股权。在交易完成后，长沙珂信将成为盈康生命下 属控股子公司，纳入公司合并报表范围。 制图：佘诗婕 扩张医疗版图 近年来，海尔集团开始积极布局医疗健康领域。 据悉，苏州广慈肿瘤医院是一所二级甲等肿瘤医院。 除了上述3家医院，盈康生命旗下还有上海永慈康复医院等7家托管机构。 此次"拿下"长沙珂信这家三级肿瘤医院，也可以说是符合盈康生命战略的重要落子。盈康生命早年提出"1+n"战略（即1家区域中心医院带动多家卫星医 院），通过并购与托管加速区域医疗中心布局。 对于这次并购，盈康生命表示，并购标的肿瘤医疗服务收入占比高，将有力强化公司在肿瘤特色医疗领 域的战略布局。 增值率1429.99% 据了解，此前盈康生命就已与湖南珂信健康产业集团有限公司（下称"珂信集团"）、长沙珂信签署相关协议。根据协议，珂信集团向盈康生命承诺，长沙 珂信2025年度、 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 11.97 RMB [6][7]. Core Views - The company achieved a revenue of 1.559 billion RMB in 2024, representing a year-on-year growth of 6.01%, and a net profit of 115 million RMB, up 14.92% year-on-year, slightly below the consensus forecast of 120 million RMB [1][5]. - The hospital business is expanding steadily, driven by the strengths of Sichuan Friendship Hospital in oncology and the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million RMB, which will enhance the company's oncology business layout [1][2]. - The medical device segment is focusing on high-end and international strategies, with a revenue of 367 million RMB in 2024, reflecting a 14% year-on-year increase [4]. Summary by Sections Hospital Business - The hospital business generated 1.19 billion RMB in 2024, growing by 3.76% year-on-year, primarily due to stable revenue growth from Sichuan Friendship Hospital's oncology services [2]. - Sichuan Friendship Hospital achieved a revenue of 579 million RMB in 2024, up 10% year-on-year, with expectations for continued growth in 2025 [2]. - The acquisition of Changsha Kexin Tumor Hospital is expected to boost revenue, with the hospital generating 273 million RMB in revenue and a net profit of 33.43 million RMB in the first nine months of 2024 [2]. Medical Devices - The medical device segment's revenue reached 367 million RMB in 2024, driven by high-end product upgrades and breakthroughs in overseas markets [4]. - The company anticipates stable growth in this segment for 2025, supported by the recovery of Gamma Knife orders and the performance of Saint Nuo and Shenzhen Unimedic [4]. Profit Forecast and Valuation - The company forecasts earnings per share (EPS) of 0.19 RMB, 0.23 RMB, and 0.26 RMB for 2025, 2026, and 2027 respectively, with a target price set at 11.97 RMB based on a 63x price-to-earnings (PE) ratio for 2025 [5][6]. - The projected revenue for 2025 is 1.933 billion RMB, reflecting a year-on-year growth of 23.95% [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's hospital segment shows steady growth, while the medical device segment has achieved breakthroughs in international markets [1] - In 2024, the company achieved total revenue of 1.559 billion yuan, a year-on-year increase of 6.01%, and a net profit attributable to shareholders of 115.42 million yuan, up 14.92% year-on-year [7] - The company continues to deepen its specialty in oncology services and leverage AI innovations for upgrades [7] - The acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan is expected to enhance the company's hospital business capabilities [7] - The forecast for net profit attributable to shareholders for 2025-2026 has been adjusted down to 116 million yuan and 174 million yuan, respectively, with an expected net profit of 215 million yuan in 2027 [7] Financial Summary - Total revenue is projected to grow from 1.559 billion yuan in 2024 to 2.412 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 8.02% [1][8] - The net profit attributable to shareholders is expected to increase from 115.42 million yuan in 2024 to 215.15 million yuan in 2027, reflecting a CAGR of approximately 23.85% [1][8] - The earnings per share (EPS) is forecasted to rise from 0.15 yuan in 2024 to 0.29 yuan in 2027 [1][8] - The price-to-earnings (P/E) ratio is projected to decrease from 67.27 in 2024 to 36.09 in 2027, indicating an improving valuation [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady business progress, with a recent acquisition of a hospital expanding its medical service footprint [5][15] - The company's 2024 annual performance met expectations, with revenue of 1.559 billion RMB, a year-on-year increase of 6.01%, and a net profit of 115 million RMB, up 14.92% [12] - The acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million RMB is expected to enhance the company's medical service capabilities [5][15] - The company is focusing on a dual-driven strategy in medical services and medical devices, anticipating continued growth in both sectors [20] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 1.559 billion RMB, with a net profit of 115 million RMB, and a significant increase in operating cash flow by 36.44% to 259 million RMB [12] - The medical services segment generated 1.192 billion RMB in revenue, a 3.76% increase, while the medical devices segment saw a 14.05% increase to 367 million RMB [12][6] - The company expects revenues of 1.821 billion RMB, 2.114 billion RMB, and 2.308 billion RMB for 2025, 2026, and 2027 respectively, with corresponding net profits of 136 million RMB, 161 million RMB, and 188 million RMB [20][9] Acquisition and Expansion - The acquisition of Changsha Kexin Tumor Hospital is projected to add significant value, with performance commitments ensuring net profits of 57 million RMB, 58 million RMB, and 60 million RMB for 2025 to 2027 [5][15] - The hospital is a comprehensive tumor specialty facility, which will enhance the company's service offerings and operational synergies [15] Strategic Outlook - The company is embracing AI in its operations, developing a three-tier AI+medical framework to enhance service delivery and operational efficiency [16] - The strategic focus on both organic growth and acquisitions in the medical services and devices sectors is expected to drive sustainable growth [20]

Core Insights - The company reported a revenue of 1.559 billion yuan for the fiscal year 2024, marking a year-on-year growth of 6.01%, and a net profit attributable to shareholders of 115 million yuan, reflecting a year-on-year increase of 14.92% [1] - The company announced plans to acquire 51% of Changsha Kexin Tumor Hospital for 357 million yuan, indicating ongoing expansion in the medical services sector [2] Financial Performance - The company's Q4 revenue for 2024 was 332 million yuan, showing a decline of 9.76% year-on-year, while the net profit for the same period was 33 million yuan, a significant increase of 415.24% [3] - For the full year 2024, the medical services revenue was 1.192 billion yuan, up 3.76% year-on-year, with a five-year CAGR of 27%, while the medical device revenue reached 367 million yuan, up 14.05% year-on-year, with a five-year CAGR of 16% [3] Acquisition Details - The target hospital, Changsha Kexin Tumor Hospital, reported revenues of 263 million yuan and 273 million yuan for 2023 and Q1-Q3 2024 respectively, with net profits of 32.93 million yuan and 33.43 million yuan, and net profit margins of 12.5% and 12.3% [3] - The acquisition includes performance commitments for the years 2025-2027, with expected net profits of 57 million, 58 million, and 60 million yuan respectively, and a cumulative net profit threshold of 175 million yuan [3] Investment Outlook - The company is expected to achieve revenues of 1.821 billion, 2.114 billion, and 2.308 billion yuan for the years 2025-2027, representing year-on-year growth rates of 16.8%, 16.1%, and 9.2% respectively [4] - The projected net profits for the same period are 136 million, 161 million, and 188 million yuan, with year-on-year growth rates of 18.1%, 18.4%, and 16.5% [4]

Core Insights - The company reported a 2024 revenue of 1.559 billion yuan, representing a 6.01% increase, and a net profit of 115 million yuan, reflecting a 14.92% growth, aligning with expectations [1] - The company is actively expanding its oncology medical service network through the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, which is expected to enhance its capabilities in the oncology sector [3] - The integration of AI in medical services is being prioritized, with significant improvements in operational efficiency and diagnostic capabilities being reported [4] Financial Performance - 2024 revenue reached 1.559 billion yuan (+6.01%), with a net profit of 115 million yuan (+14.92%) and a net cash flow from operations of 259 million yuan (+36.44%) [1] - The gross margin for 2024 was 25.86% (-2.71 percentage points), with the medical services segment at 19.65% (-5.17 percentage points) and the medical devices segment at 46.06% (+5.45 percentage points) [1] - The net profit margin was 7.40% (+0.57 percentage points), while the net profit margin excluding non-recurring items was 5.35% (-1.69 percentage points) [1] Segment Performance - The medical services segment generated 1.192 billion yuan in revenue (+3.76%), with Sichuan Friendship Hospital achieving 579 million yuan (+10.11%) and Suzhou Guangci Hospital at 524 million yuan (-2.67%) [2] - The medical devices segment reported a revenue of 367 million yuan (+14.05%), with Shengnuo Medical at 175 million yuan and Unimedik at 90 million yuan [2] Strategic Initiatives - The acquisition of Changsha Kexin Tumor Hospital is expected to enhance the company's oncology service capabilities and contribute positively to its financial performance [3] - The company is developing an AI-driven medical ecosystem, which includes various applications aimed at improving diagnostic efficiency and operational capabilities [4] Growth Projections - Revenue forecasts for 2025, 2026, and 2027 are projected at 1.877 billion yuan, 2.168 billion yuan, and 2.509 billion yuan, respectively, with net profits expected to be 134 million yuan, 160 million yuan, and 194 million yuan [6]